- Home
- IQV vs ONC Comparison
IQV vs ONC Comparison
Compare IQV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQV
- ONC
- Stock Information
- Founded
- IQV 1982
- ONC 2010
- Country
- IQV United States
- ONC Cayman Islands
- Employees
- IQV N/A
- ONC N/A
- Industry
- IQV Biotechnology: Commercial Physical & Biological Resarch
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- IQV Health Care
- ONC Health Care
- Exchange
- IQV Nasdaq
- ONC Nasdaq
- Market Cap
- IQV 26.7B
- ONC 26.9B
- IPO Year
- IQV 2013
- ONC N/A
- Fundamental
- Price
- IQV $136.91
- ONC $241.43
- Analyst Decision
- IQV Buy
- ONC Strong Buy
- Analyst Count
- IQV 20
- ONC 7
- Target Price
- IQV $226.80
- ONC $326.43
- AVG Volume (30 Days)
- IQV 2.6M
- ONC 369.7K
- Earning Date
- IQV 05-06-2025
- ONC 05-07-2025
- Dividend Yield
- IQV N/A
- ONC N/A
- EPS Growth
- IQV 0.26
- ONC N/A
- EPS
- IQV 7.35
- ONC N/A
- Revenue
- IQV $15,497,000,000.00
- ONC $4,180,740,829.00
- Revenue This Year
- IQV $5.40
- ONC $32.78
- Revenue Next Year
- IQV $5.21
- ONC $19.07
- P/E Ratio
- IQV $18.65
- ONC N/A
- Revenue Growth
- IQV 2.84
- ONC 52.09
- 52 Week Low
- IQV $134.65
- ONC $141.31
- 52 Week High
- IQV $252.88
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- IQV 36.95
- ONC N/A
- Support Level
- IQV $137.34
- ONC N/A
- Resistance Level
- IQV $145.78
- ONC N/A
- Average True Range (ATR)
- IQV 5.73
- ONC 0.00
- MACD
- IQV -0.53
- ONC 0.00
- Stochastic Oscillator
- IQV 10.35
- ONC 0.00
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.